Trial Profile

Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TROP2-CAR-NK-Cells (Primary) ; TROP2-CAR-NK-Cells (Primary) ; Cyclophosphamide; Fludarabine
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer
Focus Adverse reactions

08 Jun 2025 Planned End Date changed from 1 Jul 2028 to 15 Jan 2028.
08 Jun 2025 Planned primary completion date changed from 1 Jul 2026 to 15 Oct 2027.
04 Jun 2024 Trial design from this study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com